LONRF2P4

Across TCGA pan-cancer cohorts, LONRF2P4 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated LONRF2P4 data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher LONRF2P4 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LONRF2P4 expression acts as an unfavorable survival marker, although some lineages such as STAD and ESCA show a favorable association.

BLCA, STAD, and ESCA are the cancer types where LONRF2P4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Tertile	II,III,IV	0.359	0.721	<.001	54	view →
STAD	OS	Tertile	II,III,IV	1.000	0.633	.006	39	view →
ESCA	OS	Tertile	III,IV	0.811	0.363	.044	18	view →
PCPG	OS	Tertile	All	0.762	0.975	<.001	18	view →
THCA	OS	Tertile	All	0.911	0.982	.005	6	view →
OV	OS	Tertile	II,III,IV	0.677	0.848	.046	6	view →
KICH	DFS	Tertile	All	0.425	0.847	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LONRF2P4–BLCA (OS)

Open the BLCA breakdown →